Drug Profile
Autologus regenerative skin cell therapy - Regenicin
Alternative Names: NovaDerm; NovaDerm™ skin substituteLatest Information Update: 30 Aug 2023
Price :
$50
*
At a glance
- Originator Regenicin
- Class Cell therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Burns
Highest Development Phases
- Preclinical Burns
Most Recent Events
- 30 Aug 2023 NovaDermTM is still in preclinical development for Burns in USA (Topical)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Burns in USA (Topical)
- 18 Jan 2017 Autologus regenerative skin cell therapy - Regenicin is available for licensing as of 18 Jan 2017. www.regenicin.com